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Serum creatinine alone can be difficult to interpret as a
measure of kidney function such that chronic kidney disease
might be under-recognized in the general population. In the
province of Ontario, Canada, all outpatient laboratories now
report estimated glomerular filtration rate (eGFR) in addition
to serum creatinine. To determine the impact of this
reporting on clinical practice, we linked health administrative
data for more than 8 million adults of age 25 years or older
over an almost 10-year period and conducted a population-
based intervention analysis with seasonal time-series
modeling to determine overall trends in the number and
type of patients seen by nephrologists. Compared to the
period when only serum creatinines were reported, the
number of patients seen in consultation by nephrologists
increased after eGFR reporting by an average of 24% (an
absolute increase of 2.9 consults per 100,000 adults), an
increase of about 23 consults per nephrologist per year. The
greatest increases were seen in women (39% increase) and
those 80 years of age and older (58% increase). Our study
found that eGFR reporting was associated with a sudden
increase in the number of nephrology consults. However, it
remains to be seen whether the routine reporting of eGFR
results in improved treatment and outcomes for those with
chronic kidney disease.
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Chronic kidney disease (CKD) has been described as a global
health concern.1,2 A recent estimate suggests that about 8% of
adults have CKD stage 3 or 4, when using the US National
Kidney Foundation definition of CKD (an estimated
glomerular filtration rate (eGFR) of 15–59ml/min per
1.73m2).3 Some health professionals do not recognize the
presence of CKD. This may delay, or result in a complete loss,
of an opportunity to counsel and treat patients, improve
clinical outcomes, and reduce health-care costs.4,5 Although
timely referral to a nephrologist or a specialized nephrology
clinic is associated with improved patient outcomes, a
significant proportion of patients requiring assessment by a
nephrologist are not referred.6–8
In clinical practice, the results of the serum creatinine test
are used to estimate kidney function (GFR). However, serum
creatinine may remain normal or only mildly elevated in the
setting of CKD. Reliance upon serum creatinine alone has
been suspected to lead to underdiagnosis of CKD.9,10 The
under-recognition of CKD is particularly prominent among
women and the elderly.11,12
To improve CKD recognition, several international
societies now recommend that kidney function be directly
estimated with the use of an equation.13–15 Using the
Modification of Diet in Renal Disease equation, a serum
creatinine value along with the patient’s age, sex, and race are
used to calculate a better estimate of GFR than simply using
the serum creatinine alone.16 The addition of such informa-
tion to a laboratory report is termed ‘eGFR reporting.’
Estimated glomerular filtration rate reporting has been
implemented in various regions around the world and has
been the subject of intense debate.17–18 A recent survey
confirms an increasing trend in the adoption of eGFR
reporting among clinical laboratories; as of 2008, it was
implemented in 70% of laboratories.19 Proponents believe
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that it improves the detection of early kidney disease.20,21
Others believe eGFR reporting may inappropriately label
some patients who do not have a progressive pathological
process as having CKD, simply because their eGFR is
o60ml/min per 1.73m2. This could result in a large number
of unnecessary consults to nephrologists, making eGFR
reporting an overly sensitive ‘screening test.’22–24
Regardless of one’s position on eGFR reporting, its
widespread use necessitates accurate assessments of its
impact. Knowledge of the effects of outpatient eGFR
reporting on the number of nephrology consults performed
and the demographics of patients seen would inform this
debate. It would help guide the adoption of this reporting
strategy in other regions.
Therefore, we conducted a population-based study to
determine the effect of eGFR reporting on consults to
nephrologists.
RESULTS
Nephrologist consults
The number of new outpatient consults seen by nephrologists
in Ontario, which were non-urgent and where the patient had
not previously been seen by a nephrologist, was about 1531
per month in the year before eGFR reporting. This meant
that each nephrologist, on average, saw about 134 such
consults in 2005.
The number of ‘new nephrology consults’ from January
2003 through September 2007 are presented in Figure 1. A
consistent seasonal variation was seen in the series, with
nadirs coinciding with the traditional vacation periods
during late summer and December. The number of patients
seen in consultation increased after the introduction of eGFR
reporting. The step function characterized this as an increase
of 24% (95% confidence interval (CI) 16–31) or an absolute
increase of 2.9 consults per 100,000 adult population per
month (95% CI 2.5–3.4). This translated into a crude increase
of about 3433 consults per year for Ontario (286 per month
(95% CI 170–402)), or an average of about 23 consults per
nephrologist per year.
We considered the consult rate in different segments of the
population. There was an increase in the consult rate after
eGFR reporting for both women and men. The percent
increase was greater in women compared with that in men
(Po0.01). The percentage increase among women was 39%
(95% CI 28–51) and the increase among men was 14% (95%
CI 4–24). This translated to an increase in the absolute
number of consults per month for women of 207 (95% CI
147–267) and 86 (95% CI 23–148) for men. There was a
greater percent increase among the elderly (X70 years old)
compared with younger adults (o70 years old); Po0.001.
We observed a graded increase in the consult rate after eGFR
reporting among older patients aged 60–69, 70–79, and X80
years old, respectively (see Table 1). The largest percent
increase was among patients aged 80 years old or more (an
increase of 58%, 95% CI 35–80). Changes in the consultation
rate after eGFR reporting were no different among non-
diabetic patients compared with those in diabetic patients.
Additional analyses
The tracer outcome, dermatology consults, exhibited the
same seasonal variations in rate as nephrology consults. eGFR
reporting had no effect on dermatology consults (P¼ 0.16).
There were seasonal variations noted for the laboratory tests,
which were assessed, with nadirs noted in the late summer
and December time periods. Serum creatinine is presented as
a graph representative of all laboratory tests (Figure 2). There
was an increasing trend in the absolute number of serum
creatinine tests performed over time. However, there was no
significant effect of eGFR reporting on any of the laboratory
tests (all P-valuesX0.11).
To
ta
l n
ep
hr
ol
og
ist
 c
on
su
lts
 p
er
 m
on
th 3000
2500
2000
1500
1000
500
0
Study year
Jan
 
03
Jun
 
03
Jan
 
04
Jun
 
04
Jan
 
05
Jun
 
05
Jan
 
06
Jun
 
06
Jan
 
07
Jun
 
07
Pre-eGFR reporting Post-eGFR reporting
Number of consults observed
Expected number of consults
95% Cl
Figure 1 |Age- and sex-standardized number of nephrologist
consults in Ontario.
Table 1 | Increase in consult rate for various age categories
Age
(years)
Percentage increase in
number of consults (95% CI)
Change in total number of
consults each month (95% CI)
25–49 1.7 (17.0 to 20.3) 4.4 (44.6 to 53.3)
50–59 8.8 (4.2 to 21.8) 19.5 (9.3 to 48.3)
60–69 25.6* (12.1–39.0) 58.0* (27.4–88.6)
70–79 38.7* (26.7–50.6) 113.7* (78.6–148.9)
X80 57.8* (35.3–80.2) 78.0* (47.7–108.3)
CI, confidence interval.
*P-valueo0.0005.
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Figure 2 |Number of creatinine tests for adults in Ontario.
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DISCUSSION
In this study, eGFR reporting was associated with a
significant and sudden increase in the number of new
nephrology consults. The greatest increase was noticed
among women and the elderly. As expected, there was a
short 3-month period after the initiation of eGFR reporting
where there was no increase in the consult rate (representing
the lag time it takes for the lab test to be ordered and
completed, referral to be made, and consult to be seen).
Some would conclude that outpatient eGFR reporting
resulted in an increased awareness of CKD in the community,
triggering an appropriate increase in referrals. This is
supported by the results of some smaller studies25–28 and by
the fact that women and the elderly were differentially
affected by eGFR reporting (the populations in which CKD is
least likely to be recognized). The implementation of eGFR
reporting occurred in the absence of a provincially mediated
comprehensive education program, suggesting that reporting
practices themselves led to the increase in consult rates. This
may have triggered the increased awareness of CKD.
However, others may question whether this increased rate
of consultation truly reflects an increased recognition of
CKD. Some believe that it is inappropriate to diagnose CKD
in elderly individuals on the basis of an eGFR of 45–60ml/
min per 1.73m2, because some of these people are unlikely to
progressively lose kidney function.29,30 Labeling these in-
dividuals as having CKD is incorrect because their decrease in
GFR may simply represent a normal, age-related decline in
kidney function.
If eGFR reporting resulted in a large increase in
inappropriate referrals, its utility as a screening test could
be questioned.31 Although examining the laboratory results
of referred patients could help determine consult appropri-
ateness as defined by various guidelines, only the fact that a
test was performed is collected in administrative databases
for Ontario. Thus, we could not determine the actual eGFR
or serum creatinine level that initiated the consult, the rate of
decline of kidney function, or other issues (for example,
evidence of concurrent hypertension or proteinuria). Noble
et al.32 found that eGFR reporting was associated with both
an increase in inappropriate referrals and an increase in
appropriate referrals, as defined by the Kidney Check
Australia Taskforce. As well, some could argue that any
consult by a primary care physician to a specialist is
appropriate, as it helps clarify a patient’s diagnosis and
future management. It is possible that the increased consult
rate we observed may subside over time as primary care
physicians become more familiar with eGFR reporting. This
has been noted by others and may bring into question the
increased awareness of CKD attributed to eGFR reporting.33
The limitations of this study need to be considered. We
were not able to assess the number of referrals made to
nephrologists or the reason for consultation. Instead, we
could only determine that a consult was preformed. Consults
seen by salaried physicians were not included; however, this
represented only 5% of the physicians in Ontario. The
appropriateness of referrals could not be assessed nor did we
consider which physicians were referring the patients. Other
contemporaneous events (for example, guidelines, educa-
tional efforts, and changes in billing practices) could have
influenced the consult rate. However, when reviewing the
literature and polling physicians across Ontario, we found no
such publications or events that coincided with the dramatic
and sudden increase in consultations observed after eGFR
reporting. We could not assess the impact of eGFR reporting
on wait times or if it resulted in a delay for nephrologists to
see more urgent cases. Although we have attributed the
changes to eGFR reporting, it may truly be the laboratory
prompt that is causing these changes.
When we considered all outpatient lab tests performed for
the entire province of Ontario (about 8.9 million adults), the
number did not change after eGFR reporting. This finding
may be explained by three factors. First, the volume of tests
performed in Ontario was much larger than the number of
patients with CKD. For example, on a monthly basis, there
were approximately 400,000 outpatient serum creatinine tests
performed. If eGFR reporting increased testing in patients
seen by nephrologists, or resulted in repeat testing by the
primary care physician, this increase would still be a minor
component of the absolute number of tests performed.
Second, lab tests performed in hospitals were not captured in
the provincial databases. Therefore, we were unable to assess
the impact of eGFR reporting on hospital-based laboratory
utilization. Finally, some tests, for example renal ultrasounds,
do not have unique codes in Ontario health administrative
data. Instead, similar tests were aggregated together at the
billing level. In the case of renal ultrasounds, all types of
abdominal ultrasounds were grouped together. Therefore,
these types of tests were not assessed.
We believe that the introduction of eGFR reporting was
truly associated with an increase in the number of consults
seen by nephrologists. To our knowledge, this is the first
study to rigorously assess the impact of eGFR reporting on
nephrologist consults in a large cohort of adults. Our data are
population based and are comprehensive given the single-
payer structure of health care in Ontario. Our exclusion
criteria have effectively eliminated most non-routine con-
sults, which would be seen by nephrologists (that is, urgent
and emergency room consults).
One of the concerns about eGFR reporting is that it could
overwhelm nephrologists with a large number of consults.34
The prevalence of CKD stage 3 or 4 is estimated at 8% or
about 640,000 adults in Ontario. This raises the potential for
large increases in the number of nephrology consultations if a
substantial proportion of these were referred in response to
eGFR reporting. However, there was only a modest increase
of 3433 consults per year after eGFR reporting (23 per
nephrologist per year), which seems unlikely to have a
dramatic effect on wait times.
Another concern about eGFR reporting is costs to the
health-care system. We could not perform a comprehensive
economic assessment; however, based solely on the number
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of ‘first time’ consults observed, the increase in nephrologist
billings was about half a million dollars per year. An increase
in laboratory tests could have great cost implications for the
health-care system. In this study, eGFR reporting was not
accompanied by an increase in the frequency of laboratory
testing at the population level. However, it remains possible
that the number of tests among those with CKD changed.
The rationale behind eGFR reporting is that most patients
with a low GFR will benefit from having been recognized and
that ultimately this recognition will lead to improvement in
patient outcomes, including the prevention of death and
kidney failure. Studying such outcomes is difficult due to the
prolonged time needed to identify them and their rare
occurrence. During this time, other secular changes and
medical advances would hamper an assessment of this
intervention, particularly at the population level. The only
true way to establish a causal relationship on such outcomes
would be through a cluster randomized trial in which regions
were randomized to receive eGFR reporting or not. However,
such a study would offer a number of logistical challenges
and the results would not be available for many years if ever.
In the meantime, our assessment may help regions currently
deliberating on whether to adopt eGFR reporting to
anticipate changes in the utilization of health-care resources,
before its adoption.
MATERIALS AND METHODS
Study setting
Ontario is Canada’s most populous province (38% of the Canadian
population), currently with about 12 million residents, of which 8.9
million are adults. Ontarians have universal access to health care,
including hospital care, physician visits, and laboratory services,
through a single provincial government payer. In this structure, a
consult is generated by a physician, usually a primary care physician,
by sending a referral letter to a nephrologist. A referred patient is
then booked and is subsequently seen by a nephrologist in
consultation, and the nephrologist bills the government a pre-
defined fee for their service (Ontario Health Insurance Program).
During the study period (July 1999 to September 2007), about 67%
of Ontarians were aged 25 years or older, with 12% exceeding 65
years of age; 51% were women; 6–9% of adults had diabetes;35,36
3.6% were African Canadians; and emigration was less than 1% per
year (2001 Canadian Census).
This study was conducted according to a pre-specified protocol,
and ethics approval was obtained from the institutional review
board at Sunnybrook Health Sciences Centre, Toronto, Canada.
Intervention
In January 2006, Ontario medical laboratories began adding eGFR
results (using the abbreviated Modification of Diet in Renal Disease
study equation37) to serum creatinines on their laboratory reports.38
All serum creatinine reports had the patient’s eGFR result and lab
prompt appended to it. This change affected all adult outpatient
tests. Hospital-based laboratories were not required to report eGFR.
This change in reporting was implemented without a concurrent
educational effort at the provincial level. All eGFRs were presented
with a laboratory prompt that included an explanation of eGFR
ranges (see Table 2). The same prompts were used regardless of age,
sex, or race. Medical laboratories continued to report a serum
creatinine level along with reference ranges.
Data sources
All outpatient laboratory tests and physician visits are recorded in
the Ontario Health Insurance Program database. Each claim cites
the patient, test or visit type, and service date. This database does
not include claims submitted by salaried physicians (about 5% of
health-care providers in Ontario). Importantly, there was no change
in the percentage of physicians who were salaried during the study
period. The Canadian Institute for Health Information Discharge
Abstract Database (CIHI-DAD) records information about all
Ontario hospitalizations. The Ontario Drug Benefit Database
(ODBD) records all prescriptions filled to elderly Ontarians. The
Registered Persons Database (RPD) records dates of birth, death,
and place of residence. The Ontario Diabetes Database (ODD)
identifies individuals in Ontario who have diabetes. Finally, the
Institute for Clinical Evaluative Sciences (ICES) Physician Database
(IPDB) records the specialty of all physicians practicing in Ontario.
These databases were linked with encrypted, 10-digit health card
numbers and have been extensively used in health-utilization and
outcomes research.39–42
Population
All Ontarians, at least 25 years old, were included in the study. We
chose a cutoff age of 25 years to avoid consults from pediatric
patients who are making the transition to adult nephrology care. We
excluded individuals who did not have a valid health card number.
On the basis of physician billings recorded in the Ontario Health
Insurance Program database, people on chronic dialysis or those
having undergone renal transplantation in the previous 4 years were
also excluded.
Primary outcome
The primary study outcome was the number of new outpatient
nephrologist consults seen each month that was non-urgent. We
hypothesized that there would be a significant increase in the
number of consults seen by nephrologists. A ‘new nephrologist
consult’ was a consult claimed by a nephrologist, where the patient
had not been billed for a nephrologist consult in the past 4 years
(billing code A135). Non-urgent consults were defined as those
consults that were not billed as urgent or from the emergency room.
We did not assess the diagnostic codes for each consult as these data
Table 2 | Typical eGFR reporting laboratory prompts for
patients of varying degrees of kidney function
eGFR*90–120 Normal eGFR.
eGFR*60–89 Slightly reduced eGFR is seen in approximately 30% of
adults 20 years or older. Rule out kidney damage in
those at high risk for chronic kidney disease.
eGFR*30–59 Consistent with moderate chronic kidney disease if
result confirmed by repeat measurement, with
persistence for 3 months or more.
eGFR*15–29 Consistent with severe chronic kidney disease.
eGFR*o15 Consistent with kidney failure.
eGFR, estimated glomerular filtration rate.
All reports were followed by: for African Americans, the reported eGFR should be
multiplied by a factor of 1.21 and re-interpreted accordingly.
*eGFR measured by abbreviated MDRD equation in ml/min per 1.73m2.
Source: personal communication with Gamma-Dynacare, one of the largest
outpatient laboratories in Ontario.
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have not been validated. Nephrologists were defined as physicians
who billed for chronic dialysis (for at least 10 weeks) and saw at least
10 new consults (A135) per year. Each year, a new list was generated
to identify new and active nephrologists, as well as to remove
retirees. This definition of nephrologist identified similar numbers
of nephrologists in Ontario as described in the IPDB (a difference in
number of less than 10% for years 1999–2005).
Statistical analysis
Beginning in January 1999 and ending in December 2005, the total
number of consults and their demographics were recorded on a
monthly basis. There were 84 months of data before eGFR reporting
was implemented, providing us adequate power for this study.43 We
then examined the monthly results from January 2006 until
September 2007, giving us 21 months of post-implementation data.
Temporally sequenced data are often autocorrelated and violate
the assumption of independence, thereby negating the use of
traditional regression.44 We therefore used time-series analysis to
examine patterns in health-care utilization rates during the study
period.
The association between the change in the number of consults
and eGFR reporting was assessed using interventional autoregressive
integrated moving average (ARIMA) models with a step function
and a lag of up to 3 months. This model allowed us to characterize
the change in the number of consults from the pre- to post-eGFR
reporting time periods. Autocorrelation, inverse autocorrelation,
and partial autocorrelation functions confirmed model parameter
appropriateness and seasonality. Autocorrelation functions and the
augmented Dickey–Fuller test confirmed an appropriate trend over
time (stationarity). Model adequacy was confirmed by examining
the autocorrelations at various lags with use of the Ljung–Box w2
statistic. Changes in crude, percentage, and standardized outcomes
were compared with forecasted values.45 Subgroups were pre-
specified and analyzed by assessing the difference between parameter
estimates of change (that is, intervention effect or step function)
using a conservative pooled estimate of standard deviation, as the
intervention effect followed a normal distribution.44 All P-values
were two-sided and a value of less than 0.05 was considered
significant.
Statistics Canada provided census data on the number of people
within each sex and age category in Ontario on 1 July of each study
year. To determine the population for each time interval (month),
linear extrapolation was applied between 1 July estimates for
successive years. Crude and age- and sex-standardized rates for
nephrology consults were calculated and analyzed. For the primary
outcome, age- and sex-standardized rates were used to remove any
changes that may have resulted from changes in the population
structure over time.46 For laboratory tests, crude totals on a monthly
basis were tabulated. All analyses were performed using R for
Windows, Version 2.6.1.47
Additional analyses
With regard to nephrology consults, we expected that eGFR
reporting would differentially impact the number of consults among
women and the elderly. Kidney function is routinely overestimated
in these patients when using serum creatinine alone; with a marked
reduction in GFR, there is often only a modest increase in serum
creatinine. We believed that there would be a greater percent change
in the number of consults for women and for the elderly (X70 years
old) compared with men and younger adults (o70 years old),
respectively. As well, we hypothesized that there would be a
differential effect on diabetics compared with non-diabetics.
Diabetics have routine kidney-related screening (for example, serum
creatinine and microalbumin to creatinine ratio). Therefore, eGFR
reporting may not have as great an impact on them as it does on
non-diabetics.
We conducted several additional analyses for this study. First, as
a control or tracer outcome for the primary outcome, dermatology
consults were examined in a similar fashion. It was expected that
dermatology consults would not be influenced by eGFR reporting,
but could be affected by other secular health-care factors should they
exist. Second, we examined trends in the use of outpatient
diagnostic tests associated with kidney disease. We assessed the
absolute number of outpatient tests performed in Ontario for serum
creatinine, serum urea, renal biopsy, timed urine collections for
creatinine clearance, urinalysis, and nuclear medicine GFR. We
included all outpatient tests ordered for the adult population of
Ontario. We hypothesized that eGFR reporting would increase the
number of tests that were performed.
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